Cornelia Ciorciaro
Roche (Switzerland)(CH)
Publications by Year
Research Areas
Atrial Fibrillation Management and Outcomes, Pharmacovigilance and Adverse Drug Reactions, Pharmaceutical studies and practices, Blood Coagulation and Thrombosis Mechanisms, Computational Drug Discovery Methods
Most-Cited Works
- → A novel and selective sodium‐glucose cotransporter‐2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus(2015)72 cited
- → First-in-man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin(2015)55 cited
- [Differences in the relative incidence of adverse drug reactions in relation to age? An evaluation of the spontaneous reporting system of SANZ (Swiss Drug Monitoring Center)].(1998)
- → Crossover Dose Escalation Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of R1663, an Oral Factor Xa Inhibitor, in Healthy Male Volunteers(2011)6 cited
- [Liver injury caused by coumarin anticoagulants: experience of the IKS (Intercanton Monitoring Station) and the SANZ (Swiss Center for Drug Monitoring)].(1996)
- → Signal generation in a non-EU country(1997)5 cited
- [Clostridium difficile associated diarrhea in cephalosporin administration: experiences of the Swiss Adverse Drug Reaction Reporting System 1981-1995].(1997)
- → Safety, pharmacokinetics and pharmacodynamics of multiple ascending doses of R1663, an oral factor Xa inhibitor, in healthy young subjects coupled with exploration of influence of gender and age(2012)2 cited
- → Absence of Pharmacodynamic Interaction Between Inclacumab and Heparin in Healthy Smokers(2015)2 cited
- → Effect of food on the pharmacokinetics and pharmacodynamics of R1663, an oral factor Xa inhibitor, in healthy male volunteers(2012)2 cited